Ehave Announces MetaHealthU Will Enter The Market With A Focus On HPPD
Ehave Inc. (EHVVF) and University of Melbourne are launching a series of studies to better understand a condition called hallucinogen-persisting perception disorder (HPPD). Basically, HPPD is when someone continues to experience visual hallucinations after a trip.
Researchers will conduct genetic analysis and visual processing tests to see if individuals can be genetically predisposed to HPPD.
Ehave’s goal is to find a cure for the disorder and become an “industry leader in preventing negative side effects during treatment for mental health issues.”